Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 301–400 of 991
Hamada, K., Isobe, J., Hattori, K., Hosonuma, M., Baba, Y., Murayama, M., Narikawa, Y., Toyoda, H., Funayama, E., Tajima, K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164724 · Cited by 60
MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
Cui, J., Wang, L., Tan, Z., Zhou, H., Zhan, X., & Yin, J. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21620 · Cited by 52
Qin, B., Jiao, X., Zhou, X.-C., Shi, B., Wang, J., Liu, K., Wu, Y., Ling, Y., & Zang, Y. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1929727 · Cited by 51
“conducted a prospective study of a cohort of melanoma patients receiving CTLA-4 inhibitor, found that the development of ICIassociated colitis could correlate with specific intestinal microflora.(40) Patients in the non-colitis group had a higher abundance of Bacteroidetes.”
BackgroundThe double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
Kuchroo, J. R., Hafler, D. A., Sharpe, A. H., & Lucca, L. E. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf4034 · Cited by 53
“After CTLA-4 blockade therapy, patients who developed checkpoint blockade–associated colitis had a lower representation of bacteria from the phylum Bacteroidetes, suggesting that the microbiome could affect risk of irAE development (148).”
BackgroundThe Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer
Cianci, R., Franza, L., Schinzari, G., Rossi, E., Ianiro, G., Tortora, G., Gasbarrini, A., Gambassi, G., & Cammarota, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030501 · Cited by 54
“For example, the presence of Bacteroidetes phylum appears to have a protective effect against checkpoint-blockade-induced colitis [139].”
BackgroundImpact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
Pezo, R. C., Wong, M., & Martin, A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819870911 · Cited by 55
Targeting tumor-resident mast cells for effective anti-melanoma immune responses
Kaesler, S., Wölbing, F., Kempf, W. E., Skabytska, Y., Köberle, M., Volz, T., Sinnberg, T. W., Amaral, T. M. S., Möckel, S. M. C., Yazdi, A. S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125057 · Cited by 55
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49
Mizuno, S., Ono, K., Mikami, Y., Naganuma, M., Fukuda, T., Minami, K., Masaoka, T., Terada, S., Yoshida, T., Saigusa, K., et al. (2020) · Intestinal Research · doi:10.5217/ir.2019.00084 · Cited by 51
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light
Zhang, J., Wu, K.-H., Shi, C., & Li, G. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01027-2 · Cited by 56
Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
Guo, Q., Li, Y., Dai, X., Wang, B., Zhang, J., & Cao, H. (2023) · Nutrients · doi:10.3390/nu15173722 · Cited by 53
“Previous studies have underscored the diverse biological activities that polysaccharides possess, including anti-inflammatory [10], anti-tumor [11], immune-regulating and antioxidant properties [12,13].”
BackgroundGut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A review
Nagasaka, M., Sexton, R. E., Alhasan, R., Rahman, S. B., Azmi, A. S., & Sukari, A. W. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102841 · Cited by 54
Mechanisms of checkpoint inhibition-induced adverse events
Urwyler, P., Earnshaw, I., Bermudez, M., Perucha, E., Wu, W., Ryan, S. E., Mcdonald, L., Karagiannis, S. N., Taams, L. S., Powell, N., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13421 · Cited by 56
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 51
Ford, M., Sahbudin, I., Filer, A. D., Steven, N. M., & Fisher, B. A. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key234 · Cited by 48
Reynolds, K. L., Arora, S., Elayavilli, R. K., Louv, W. C., Schaller, T. H., Khandelwal, A., Rothenberg, M. L., Khozin, S., Guidon, A. C., Dougan, M. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002896 · Cited by 49
Elkrief, A., Waters, N. R., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N. D., Lumish, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0498 · Cited by 48
The dark side of immunotherapy
Okwundu, N., Grossman, D., Hu‐Lieskovan, S., Grossmann, K. F., & Swami, U. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4750 · Cited by 52
Bastacky, M. L., Wang, H., Fortman, D. D., Rahman, Z., Mascara, G. P., Brenner, T., Najjar, Y. G., Luke, J. J., Kirkwood, J. M., Zarour, H. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749064 · Cited by 52
Qiu, B., Zhu, L. Q., Zhang, S., Han, S., Fei, Y., Ba, F., Berglund, B., Li, L., & Yao, M. (2022) · Nutrients · doi:10.3390/nu14194083 · Cited by 56
“Bacteria belonging to Rikenellaceae_RC9 have been reported to be able to reduce inflammation by stimulating immune regulation [56].”
BackgroundCombination Immunotherapy Development in Melanoma
Eggermont, A. M. M., Crittenden, M. R., & Wargo, J. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201131 · Cited by 54
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
Sandigursky, S., & Mor, A. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0770-0 · Cited by 53
Possible Biomarkers for Cancer Immunotherapy
Otoshi, T., Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2019) · Cancers · doi:10.3390/cancers11070935 · Cited by 48
“In addition, specific gut microbiota is also reported to correlate with colitis induced by checkpoint blockade [59].”
BackgroundComplex interactions between the microbiome and cancer immune therapy
Schwartz, D. J., Rebeck, O. N., & Dantas, G. A. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1660303 · Cited by 54
Use of Fecal Microbial Transplantation for Immune Checkpoint Inhibitor Colitis
Fasanello, M. K., Robillard, K. T., Boland, P. M., Bain, A. J., & Kanehira, K. (2020) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000360 · Cited by 48
“Furthermore, microbiome analysis has been shown to identify patients at risk for irAE colitis.(5) Not only can themicrobiome help to possibly predict the response to treatment or adverse events but also, based on these relationships, it is possible that manipulation of the microbiome could aid in the management of ICI…”
BackgroundDevaux, C. A., Million, M., & Raoult, D. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01642 · Cited by 53
The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
Naqash, A. R., Kihn-Alarcón, A. J., Stavraka, C., Kerrigan, K. C., Vareki, S. M., Pinato, D. J., & Puri, S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6427 · Cited by 54
“…study by Dubin et al. in patients with ICPI-mediated colitis where the authors found that bacteria from the Bacteroidetes phylum family ( Bacteroidaceae , Rikenellaceae , and Barnesiellaceae ), that form a major phyla of human gut microbes were enriched in colitis-resistant patients (41).”
Taylor, J., Gandhi, A., Gray, E. S., & Zaenker, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991433 · Cited by 51
“(64) also reported an increase in fecal Bacteroidetes in baseline samples of metastatic melanoma patients who did not develop any colitis on ipilimumab treatment.”
BackgroundGao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 54
“…species such as Bacteroides xylanisol-vens , P. copri and Phocaeicola plebeius at baseline has been associated with resistance to ICI-induced colitis and other irAEs in independent cohorts of patients receiving anti-CTLA4 antibodies for advanced-stage solid tumours, predominantly melanoma 31,86 .”
Gut microbiome and cancer immunotherapy
Sun, J., Yin, T., Zhou, J., Jiang, X., & Lu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29359 · Cited by 52
“In a prospective study on metastatic melanomas patients, analysis demonstrated that increased representation of Bacteroidetes was associated with enhanced resistance to ICIs‐induced colitis (Dubin et al., 2016).”
BackgroundMechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
Westdorp, H., Sweep, M. W. D., Gorris, M. A. J., Hoentjen, F., Boers‐Sonderen, M. J., van der Post, R. S., van den Heuvel, M. M., Piet, B., Boleij, A., Bloemendal, H. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.768957 · Cited by 54
“A prediction model using molecular levels of these polyamine transport units showed a sensitivity of 70% and a specificity of 100% for resistance to IMC development, indicating all patients that were predicted to develop IMC indeed did so, however, 30% of patients were false negatively assigned to remain free of IMC (…”
MethodWang, L., Mo, Y. Y., Huang, Y., Echeveste, C. E., Wang, H., Chen, J., Oshima, K., Yearsley, M., Simal‐Gandaraf, J., Battino, M., et al. (2020) · eFood · doi:10.2991/efood.k.200824.002 · Cited by 45
“As stated above, several clinical trials, particularly in melanoma patients, have repeatedly shown that the composition and diversity of the gut microbiota at baseline influences responses to cancer immunotherapy [41-46].”
BackgroundShatila, M., Zhang, H. C., Thomas, A. S., Machado, A. P., Naz, S., Mittal, N., Catinis, C., Varatharajalu, K., Cruz, C. C., Lu, E., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009742 · Cited by 52
Fernandes, R., Jabbarizadeh, B., Rajeh, A., Hong, M. M. Y., Baines, K. J., Ernst, S., Winquist, E., Ali, A. S., Penny, S. L., Figueredo, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04183-8 · Cited by 56
“The microbiome also appears to influence the risk of irAEs, suggesting a role for microbiota-targeted strategies in toxicity management and efficacy 11–13 .”
Advances in the understanding and management of mucositis during stem cell transplantation
Bowen, J. M., & Wardill, H. R. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000310 · Cited by 48
Immune-Related Adverse Events: A Case-Based Approach
Connolly, C. M., Bambhania, K., & Naidoo, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00530 · Cited by 47
“Patients treated with CTLA-4 therapy with a predominance of bacteria from the Bacteroidetes phylum were found to have reduced rates of ipilimumab-induced colitis (105).”
BackgroundCurrent status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
“…instance, body composition parameters (Daly et al., 2017), gender (Valpione et al., 2018), T cell repertoire, gut microbiome (Chaput et al., 2017; Dubin et al., 2016), and cytokines (e.g., IL-6 and IL-17) (Callahan et al., 2011; Valpione et al., 2018) may be involved in the pathophysiology of…”
BackgroundLiu, W., Liu, Y., Ma, F., Sun, B., Wang, Y., Luo, J., Liu, M., & Luo, Z. (2021) · Cancer Management and Research · doi:10.2147/cmar.s293200 · Cited by 51
“There was also evidence that pre-treatment intestinal microbiota can be used as biomarkers that correlate with protection against CTLA-4 blockade-associated colitis.(21,22) Pre-treatment autoimmune markers, including rheumatoid factor, antinuclear antibody, antithyroglobulin, and antithyroid peroxidase were independen…”
Background(2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 44
A ‘culture’ shift: Application of molecular techniques for diagnosing polymicrobial infections
Zhang, Y., Hu, A., Andini, N., & Yang, S. S. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.013 · Cited by 48
“Besides its high-throughput, the greatest advantage of HTS is its high degree of multiplexing, (Dubin et al., 2016; Huttenhower et al., 2012; Langille et al., 2013; Qin et al., 2010; Qin et al., 2012) which makes HTS an ideal tool for diagnosing polymicrobial infections.”
BackgroundAssociation of the Microbiota and Pancreatic Cancer: Opportunities and Limitations
Chen, Z., Zhang, S., Dong, S., Xu, H., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844401 · Cited by 44
Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Yan, J., Yang, L., Ren, Q., Zhu, C., Du, H., Wang, Z., Qi, Y., Xian, X., & Chen, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471273 · Cited by 55
Iida, Y., Harashima, N., Motoshima, T., Komohara, Y., Eto, M., & Harada, M. (2017) · Cancer Science · doi:10.1111/cas.13337 · Cited by 44
Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
Larrinaga, G., Solano-Iturri, J. D., Errarte, P., Unda, M., Loizaga‐Iriarte, A., Pérez-Fernández, A., Echevarría, E., Asumendi, A., Manini, C., Angulo, J. C., et al. (2021) · Cancers · doi:10.3390/cancers13040667 · Cited by 48
“Another interesting strategy to maximize the clinical benefit and predict treatment toxicity is the characterization of gastrointestinal microbiome [17].”
BackgroundGong, L., Wang, B., Zhou, Y., Tang, L., Zeng, Z., Zhang, H., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.628374 · Cited by 46
Mason, N. J., Chester, N., Xiong, A., Rotolo, A., Wu, Y., Yoshimoto, S., Glassman, P. M., Gulendran, G., & Siegel, D. L. (2021) · mAbs · doi:10.1080/19420862.2021.2004638 · Cited by 49
Yang, L., Sun, R., Li, J., Zhai, L., Cui, H., Fan, B., Wang, H., & Liu, H. (2022) · Soil Ecology Letters · doi:10.1007/s42832-022-0142-6 · Cited by 53
van der Kooij, M. K., Wetzels, M. J. A. L., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers‐Sonderen, M. J., Dierselhuis, M. P., de Groot, J. W. B., Hospers, G. A. P., Piersma, D., et al. (2020) · Cancers · doi:10.3390/cancers12082072 · Cited by 51
“The Bacteroidetes phylum of the intestinal microbiota has been identified to be protective against anti-CTLA-4-induced colitis by stimulating the differentiation of regulatory T-cells, thereby limiting inflammation [24].”
BackgroundLi, J., Liu, B., Li, F., He, Y., Wang, L., Kulyar, M. F., Li, H., Fu, Y., Zhu, H., Wang, Y., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.712092 · Cited by 51
Common themes in antimicrobial and anticancer drug resistance
Chifiriuc, M. C., Filip, R., Constantin, M., Pîrcălăbioru, G. G., Bleoţu, C., Burlibaşa, L., Ionica, E., Corcionivoschi, N., & Mihăescu, G. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.960693 · Cited by 41
“Besides increasing its efficiency, many members of gut microbiota such as Bacteroidaceae, Rikenellaceae, and Barnesiellaceae protect from Ipilimumab adverse events (Dubin et al., 2016).”
BackgroundZhang, Y., Cheng, S., Zou, H., Han, Z., Xie, T., Zhang, B., Dai, D., Yin, X., Liang, Y., Kou, Y., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1099063 · Cited by 52
Sánchez-Camacho, A., Torres-Zurita, A., Gallego-López, L. M. D. C., Hernández-Pacheco, R., Silva-Romeiro, S., de la Gala, M. D. C. Á., de Ceballos, E. P.-G., & de la Cruz‐Merino, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597259 · Cited by 50
Zhang, Y., Ma, W., Zhang, Z., Liu, F., Wang, J., Yin, Y., & Wang, Z. (2019) · Archives of Animal Nutrition · doi:10.1080/1745039x.2019.1591128 · Cited by 42
“and the stimulation of anti-inflammatory cytokine production (Dubin et al. 2016).”
BackgroundMu, W., Tunali, I., Qi, J., Schabath, M. B., & Gillies, R. J. (2020) · Radiology Artificial Intelligence · doi:10.1148/ryai.2019190063 · Cited by 45
“Interestingly, the gastrointestinal microbiota has also been investigated, which suggests that patients with a predominance of bacteria from the Bacteroidetes phylum have reduced rates of immune-related colitis (18).”
BackgroundBalancing Cancer Immunotherapy Efficacy and Toxicity
Johnson, D. B., Jakubovic, B. D., Sibaud, V., & Sise, M. E. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.028 · Cited by 49
“Proposed mechanisms of toxicity include T-cell targeting of shared antigens common to both tumor and inflamed tissue,(15,16) preexisting autoantibodies,(17,18) and microbial factors (specifically cross-reactive memory T-cell response to a pathogen to which the host has previously been infected) inducing inflammation t…”
Wang, Y., Nan, X., Zhao, Y., Wang, Y., Jiang, L., & Xiong, B. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.01908-20 · Cited by 51
“Rikenellaceae were correlated with resistance to the development of colitis after CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) blockade and could limit inflammation by stimulating T-regulatory cell differentiation (36).”
MethodWardill, H. R., van der Aa, S., Ferreira, A. R. D. S., Havinga, R., Tissing, W. J. E., & Harmsen, H. J. M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.015 · Cited by 45
The gut microbiota and immune checkpoint inhibitors
Humphries, A., & DAUD, A. I. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1442970 · Cited by 45
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
“), during anti–CTLA-4 ICI therapy (35, 109).”
Triantafyllou, E., Gudd, C. L. C., & Possamai, L. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01019-7 · Cited by 53
“There are some suggestions for distinct bacterial signatures associated with different irAEs and well-characterized species (for example, Bacteroides and Bifidobacterium ) associated with ICI-colitis, which have shown potential for modification 101,102 .”
Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge
Kostine, M., Chiche, L., Lazaro, E., Halfon, P., Charpin, C., Arniaud, D., Rétornaz, F., Blanco, P., Jourde‐Chiche, N., Richez, C., et al. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.01.004 · Cited by 44
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Zhang, J., Liu, D., Li, G., Staveley-O’Carroll, K. F., Graff, J. N., Li, Z., & Wu, J. D. (2017) · Science Advances · doi:10.1126/sciadv.1602133 · Cited by 40
Conducting metagenomic studies in microbiology and clinical research
Martin, T. C., Visconti, A., Spector, T. D., & Falchi, M. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9209-9 · Cited by 48
Immune checkpoint inhibitor–related luminal GI adverse events
Kröner, P. T., Mody, K., & Farraye, F. A. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.09.009 · Cited by 43
Synthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside
Ding, S., Alexander, E., Liang, H., Kulchar, R. J., SINGH, R. K., Herzog, R. W., Daniell, H., & Leong, K. W. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00482 · Cited by 51
The promise and challenge of cancer microbiome research
Manzoor, S. S., Doedens, A. M., & Burns, M. B. (2020) · Genome biology · doi:10.1186/s13059-020-02037-9 · Cited by 43
“This issue is manageable, however, given that patients who develop or did not develop colitis after anti-CTLA-4 therapy have distinct microbial communities [35], IL-10 mouse models show Bifidobacteria may prevent colitis after anti-CTLA-4 therapy [97], and FMT may prove effective [98].”
BackgroundThe Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions
Sernoskie, S. C., Jee, A., & Uetrecht, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000090 · Cited by 45
“A recent investigation demonstrated that ipilimumab altered microbiome composition and the subsequent risk of colitis (Dubin et al., 2016).”
BackgroundHammond, S., Olsson-Brown, A. C., Grice, S., Gibson, A., Gardner, J., Castrejón-Flores, J. L., Jolly, C., Fisher, B. A., Steven, N. M., Betts, C. J., et al. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab144 · Cited by 45
“Indeed, several studies have shown associations between microbiome composition and the efficacy/ toxicity profiles of ICIs (Chaput et al., 2017; Dubin et al., 2016; Gori et al., 2019; Pezo et al., 2019), which may reflect discrepancies in the tolerance thresholds to particular microbial organisms.”
The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy
Gholami, H., Chmiel, J. A., Burton, J. P., & Vareki, S. M. (2023) · Cancers · doi:10.3390/cancers15041300 · Cited by 43
Effects of periodontitis on cancer outcomes in the era of immunotherapy
Pai, S. I., Matheus, H. R., & Guastaldi, F. P. S. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00021-1 · Cited by 49
Lo, J. W., Cozzetto, D., Alexander, J. L., Danckert, N. P., Madgwick, M., Knox, N., Sieh, J. Y. X., Olbei, M. L., Liu, Z., Ibraheim, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41798-2 · Cited by 49
“In another study, which only reported baseline microbiota pro fi les, a higher relative abundance of Bacter-oidota was correlated with protection against CPI-induced colitis 22 .”
BackgroundOrberg, E. T., Meedt, E., Hiergeist, A., Xue, J., Heinrich, P., Ru, J., Ghimire, S., Miltiadous, O., Lindner, S., Tiefgraber, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00669-x · Cited by 49
“Purine metabolism was recently linked to efficacy of immunotherapy 31 , while vitamin B synthesis 32 was associated with protection from colitis.”
Past, present, and future of microbiome-based therapies
Manrique, P., Montero, I., Fernández-Gosende, M., Martínez, N., Hidalgo-Cantabrana, C., & Ríos-Covián, D. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2023.80 · Cited by 50
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., & Gutzmer, R. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128 · Cited by 49
MAIT Cells: Partners or Enemies in Cancer Immunotherapy?
Cogswell, D. T., Gapin, L., Tobin, H., McCarter, M. D., & Tobin, R. P. (2021) · Cancers · doi:10.3390/cancers13071502 · Cited by 38
“Furthermore, low levels of B-vitamin producing bacteria have been associated with higher risks of immunotherapy-related adverse events [100] and less MAIT cell reconstitution in patients with blood disorders after a hematopoietic cell transplantation [101].”
BackgroundHuman Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments
Vitorino, M. M., de Almeida, S. B., Costa, D. A., Faria, A., Calhau, C., & Braga, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.815772 · Cited by 47
“Bacteroidetes phylum is enriched in colitis-resistant patients and is consistent with an immunomodulatory role of these commensal bacteria (51).”
BackgroundThe gut microbiome and melanoma: A review
Makaranka, S., Scutt, F., Frixou, M., Wensley, K. E., Sharma, R., & Greenhowe, J. (2022) · Experimental Dermatology · doi:10.1111/exd.14639 · Cited by 43
Fujimoto, A., Toyokawa, G., Koutake, Y., Kimura, S., Kawamata, Y., Fukuishi, K., Yamazaki, K., & Takeo, S. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14063 · Cited by 43
Diet-microbiome interactions in cancer
Abdeen, S. K., Mastandrea, I., Stinchcombe, N., Puschhof, J., & Elinav, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.013 · Cited by 36
Vilariño, N., Bruna, J., Kalofonou, F. H., Anastopoulou, G. G., & Argyriou, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165774 · Cited by 39
“In a study of patients with metastatic melanoma undergoing ipilimumab treatment, Bacteroidetes phylum was correlated with resistance to the development of immune-related colitis [63].”
BackgroundAmatjan, M., Li, N., He, P., Zhang, B., Mai, X., Jiang, Q., Xie, H., & Shao, X. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s389811 · Cited by 40
“To show the distribution of each species in the sample, the OTU frequency analysis was used to observe the abundance of the species present in different samples.(37) The richness, evenness and diversity of microbial communities can be reflected by calculating the alpha diversity index of the samples.”
MethodAnalysis of the Microbial Intestinal Tract in Broiler Chickens during the Rearing Period
Stamilla, A., Ruiz‐Ruiz, S., Artacho, A., Pons, J., Messina, A., Randazzo, C. L., Caggia, C., Lanza, M., & Moyá, A. (2021) · Biology · doi:10.3390/biology10090942 · Cited by 46
“As already reported [53,54], Bacteroides and Faecalibacterium decrease regulatory Tcell expansion and stimulate anti-inflammatory cytokine production.”
BackgroundGut microbiota in acute leukemia: Current evidence and future directions
Zhou, Y., Zhou, C., & Zhang, A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1045497 · Cited by 40
“Studies confirmed that a higher diversity of gut microbiota and a higher abundance of particular taxa were associated with positive responses to ICIs in patients with different types of cancer, such as melanoma, non-small cell lung carcinoma, renal cell carcinoma, and urothelial carcinoma (Dubin et al., 2016; Frankel…”
BackgroundChai, C., Guo, Y., Mohamed, T. M., Gifty, Z. B., Wang, Y., Zeng, X., Zhao, J., Du, H., Tang, Z., Xu, Y., et al. (2023) · Animals · doi:10.3390/ani13101690 · Cited by 45
“Faecalibacterium can induce the proliferation of T cells and show anti-inflammatory effects, whilst Parabacteroides is associated with weight loss of the host [64].”
BackgroundWekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103025 · Cited by 46
Microbiome as an Immunological Modifier
Kumar, M., Singh, P., Murugesan, S., Vétizou, M., McCulloch, J. A., Badger, J. H., Trinchieri, G., & Khodor, S. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_27 · Cited by 40
The Role of Gut Microbiota in Tumor Immunotherapy
Wu, M., Bai, J., Ma, C., Wei, J., & Du, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/5061570 · Cited by 39
Li, F., Neves, A. L. A., Ghoshal, B., & Guan, L. L. (2017) · Journal of Dairy Science · doi:10.3168/jds.2017-13356 · Cited by 41
Guillot, N., Roméo, B., Manesh, S. S., Milano, G., Brest, P., Zitvogel, L., Hofman, P., & Mograbi, B. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.004 · Cited by 36
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023) · Immunological Reviews · doi:10.1111/imr.13249 · Cited by 40
Yan, S., Yu, L., Tian, F., Zhao, J., Chen, W., Chen, H., & Zhai, Q. (2023) · Food & Function · doi:10.1039/d3fo03867j · Cited by 35
A Perspective on the Role of Microbiome for Colorectal Cancer Treatment
Kalasabail, S., Engelman, J., Zhang, L. Y., El-Omar, E. M., & Yim, H. C. H. (2021) · Cancers · doi:10.3390/cancers13184623 · Cited by 41
“Studies have demonstrated that enrichment of Bacteroides is associated with less frequent occurrence of ICI toxicity such as colitis when treating melanoma [72,74,75].”
BackgroundFacts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
Smithy, J. W., Faleck, D. M., & Postow, M. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1240 · Cited by 39
Daukšienė, A., Ružauskas, M., Gružauskas, R., Zavistanavičiūtė, P., Starkutė, V., Lėlė, V., Klupšaitė, D., Klementavičiūtė, J., & Bartkienė, E. (2021) · Animals · doi:10.3390/ani11030610 · Cited by 41
“Papillibacter has been reported to be isolated from the chicken gut [35,36]; however, there is still no information regarding their functions in the digestive tract of vertebrate animals.”
BackgroundFind the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
“Notably, the composition of gut microbiota also seems to be associated with ICIs-induced colitis [23,174].”
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Wan, L., Wu, C., Luo, S., & Xie, X. (2022) · Disease Markers · doi:10.1155/2022/3610038 · Cited by 42
Microbiome influencers of checkpoint blockade–associated toxicity
Wang, Y., Jenq, R. R., Wargo, J. A., & Watowich, S. S. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220948 · Cited by 37
“Bacteroidota enrichment has been associated with reduced ICI colitis or irAEs in independent studies of metastatic melanoma patients (Chaput et al., 2017; Dubin et al., 2016; Usyk et al., 2021).”
BackgroundImmune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease
Thomas, A. S., Hanauer, S. B., & Wang, Y. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.004 · Cited by 38
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.